Evaluation of left ventricular performance in hypertensive patients by speckle tracking echocardiography: Correlation with brain natriuretic peptide  by Hamed, Waleed Abdou Ibrahim et al.
The Egyptian Heart Journal (2014) 66, 299–308HO ST E D  BY
Egyptian Society of Cardiology
The Egyptian Heart Journal
www.elsevier.com/locate/ehj
www.sciencedirect.comORIGINAL ARTICLEEvaluation of left ventricular performance
in hypertensive patients by speckle tracking
echocardiography: Correlation with brain
natriuretic peptideAbbreviations: BNP, brain natriuretic peptide; BSA, body surface area;
DBP, diastolic blood pressure; DTI, Doppler tissue imaging; EF,
ejection fraction; ESH/ESC, European society of hypertension/
European society of cardiology; Esys%, peak longitudinal systolic
strain; LV, left ventricular; LVH, left ventricular hypertrophy; LVM,
left ventricular mass; LVMI, left ventricular mass index; NT-proBNP,
N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure;
SRa s1, peak late diastolic strain rate; SRe s1, peak early diastolic
strain rate; SRs s1, peak systolic strain rate; 2D-STE, two dimen-
sional speckle tracking echocardiography
* Corresponding author. Address: Cardiology Department, Meno-
uﬁya University, Shebin El-Kom, 49 Zaki Shabana st, Menouﬁya,
Egypt. Fax: +20 48 2235679.
E-mail address: waleedabdou@yahoo.com (W.A.I. Hamed).
Peer review under responsibility of Egyptian Society of Cardiology.
http://dx.doi.org/10.1016/j.ehj.2014.08.002
1110-2608 ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.Waleed Abdou Ibrahim Hamed *, Abdallah Mostafa Kamal,
Mohammed Fahmy Noamany, Mahmoud Aly Soliman,
Mai Mohammed Abdel Ra’oufCardiology Department, Menouﬁya University, EgyptReceived 25 May 2014; accepted 19 August 2014
Available online 16 September 2014KEYWORDS
Hypertension;
Speckle tracking
echocardiography;
Strain;
Strain rateAbstract Background: Hypertension results in hemodynamic changes ranging from maladaptive
left ventricular hypertrophy (LVH) to heart failure. Two-dimensional speckle tracking echocardiog-
raphy (2D-STE) allows rapid and accurate analysis of regional and global left ventricular (LV) sys-
tolic and diastolic functions.
Objective: Assessments of LV function in hypertensive patients with apparently preserved LV sys-
tolic function using 2D-STE in correlation with plasma brain natriuretic peptide (BNP) levels.
Patients and Methods: Eighty hypertensive patients were enrolled, they were classiﬁed into LVH
group (group III) and non-LVH group (group II). Twenty sex and age-matched healthy individuals
were recruited as controls (group I). 2D-STE was done to all subjects to assess LV longitudinal
strain, and strain rate (SR). Plasma BNP levels were measured in all subjects.
300 W.A.I. Hamed et al.Results: Global longitudinal systolic strain was signiﬁcantly reduced in group III compared with
group II (P= 0.037) and group I (P= 0.000). Furthermore, group III showed signiﬁcantly
reduced global LV longitudinal systolic SR and early diastolic strain rate compared with group
II (P= 0.023 and 0.008 respectively), and group I (P= 0.01 and 0.0001 respectively). On the other
hand, the mean values of global SRa s1 were signiﬁcantly higher in both group II and group III
compared to group I (P= 0.0001). A negative correlation was found between BNP level and global
peak systolic strain, global systolic strain rate, early diastolic strain rate and late diastolic strain rate
in hypertensive patients (groups II & III) in whom BNP level was signiﬁcantly higher than controls
(group I) (P= 0.000).
Conclusion: A substantial impairment of LV systolic and diastolic functions is detected in
hypertensive patients with apparently preserved LV systolic function, especially if associated with
LVH, as evidenced by two-dimensional speckle tracking echocardiography. Plasma BNP level is
elevated in hypertensive patients and shows a signiﬁcant negative correlation with strain and strain
rate values.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Hypertension is a well-recognized risk factor for cardiovascu-
lar diseases, it causes left ventricular (LV) pressure overload
which results in various geometric changes that progress to
diastolic heart failure and/or heart failure with LV systolic
dysfunction.1
Left ventricular hypertrophy (LVH) is both a major
maladaptive response to chronic pressure overload and an
important risk factor in patients with hypertension. In the
Framingham Heart Study, even borderline isolated systolic
hypertension at an elderly age was associated with increased
left ventricular wall thickness and impaired diastolic ﬁlling.2
In response to increased LV pressure load, ventricular myo-
cytes release B-type natriuretic peptide (BNP), together with its
N-terminal fragment (NT-Pro BNP), they produce diuresis,
natriuresis and vasodilatation, which reduce the load on the
heart.3
Early detection of LV dysfunction before the development
of LVH may represent a clinical ﬁnding that would justify
aggressive treatment aimed at reducing cardiovascular morbid-
ity and mortality, therefore it has to be considered in the
assessment of global cardiovascular risk.4
Several studies revealed that patients with LVH have
greater plasma levels of BNP than other patients.3 Further-
more, an increase in plasma BNP has been shown to reﬂect
the prolongation in LV relaxation time, increase in LV
end-diastolic pressure and the LV mass index (LVMI) in
patients with hypertension.5 Based on these ﬁndings, BNP
levels could be related to cardiac remodeling and diastolic
dysfunction in hypertensive patients.5
Echocardiographic strain imaging is an innovative
approach recently developed for the assessment of left ventric-
ular myocardial mechanics.6 Myocardial strain can be deter-
mined using a tissue Doppler imaging or two-dimensional
speckle tracking echocardiography (2D-STE). Doppler-based
techniques are limited by the angle-dependence of the signal,
precluding the assessment of apical left ventricular function.
In contrast, two-dimensional speckle tracking studies orthogo-
nal components of strain independent of the insonation angle
because it tracks deformation between acoustic markers in the
ultrasonic image in two dimensions.6The aim of this study was to evaluate the LV performance
in patients with hypertension using speckle tracking echocardi-
ography and correlate the ﬁndings with BNP levels.2. Subjects and methods
Hypertensive patients were selected from cardiology outpa-
tient clinic of the Menouﬁya University Hospital. Full history,
general and cardiac clinical examination were done before
selection. Written informed consent was taken from all
patients and the study protocol was approved from the Ethics
Committee of the Menouﬁya University.
This study was carried out on 80 hypertensive patients and
twenty age and sex matched healthy subjects as a control
group. Control subjects had no detectable cardiovascular
risk factors and not receiving any medications, they were
volunteers recruited from among the hospital staff, medical
and nursing students, and members of the local community.
Hypertension was diagnosed based on ESH/ESC guidelines
for management of hypertension if SBPP 140 mmHg and/or
DBPP 90 mmHg on two or more hospital visits at one week
interval.7 All patients had a complete physical examination,
including body surface area (BSA) calculation.8
2.1. Exclusion criteria
It included patients with ejection fraction <50% or with
symptoms or sign of heart failure, diabetes mellitus, patients
with known coronary artery disease, patients with signiﬁcant
valvular disease and patients with atrial ﬁbrillation or other
rhythm disturbances.
2.2. Study population grouping
Group I (control group) included twenty sex and age-matched
healthy individuals (mean age 50.5 ± 6.0 years; 8 males and
12 females), group II included 40 hypertensive patients
without echocardiographic criteria of LVH (mean age
51.6 ± 5.1 years; 16 males and 24 females) and group III
included 40 hypertensive patients with echocardiographic
criteria of LVH (mean age 52.2 ± 6.0 years, including 21
males and 19 females).
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Conventional echocardiographic Doppler study, as well as
tissue Doppler imaging and 2D-speckle tracking imaging
were performed using Vivid 9, General Electric Healthcare
(GE Vingmed, Norway) equipped with harmonic M5S vari-
able frequency (1.7–4 MHz) phased-array transducer. Images
were obtained with patients in the left lateral decubitus
position at end-expiration according to the recommendations
of the American Society of Echocardiography and connected
to single lead ECG.9 All standard measurements were obtained
in the parasternal long- and short-axis views; apical 4-cham-
ber, 2-chamber, and apical long axis views. Two-dimensional
and color Doppler imaging were performed to screen for wall
motion abnormalities, mitral annulus calciﬁcation, and
valvular stenosis or regurgitation. End diastolic ventricular
septum thickness (IVSd), end diastolic posterior wall thickness
(PWd), LV end diastolic (LVEDd) and end systolic (LVESd)
diameters were measured. Fraction shortening (FS), ejection
fraction (EF) and left ventricular mass (LVM) were calcu-
lated10, then LVM was normalized for body surface area to
obtain LV mass index (LVMI). LVH was deﬁned as LVMI
>125 g/m2 for men and >110 g/m2 for women.10 Transmitral
pulsed-wave Doppler was recorded, the peaks of both early
diastolic ﬁlling (E) and late diastolic ﬁlling (A) were measured
and the E/A ratio was calculated.
Tissue Doppler imaging was done in the apical 4-chamber
view by placing the sample volume of 5 mm over the septal
and lateral mitral annuli then the peak systolic velocity (Sm),
early diastolic velocity (Em) and late diastolic velocity (Am)
were measured. The average Em velocity at the sepal and lat-
eral mitral annuli was estimated and the E/Em ratio was
calculated.4. 2D-speckle tracking echocardiography
2D strain analysis was performed ofﬂine using the Echopac
software (General Electric version 1.8.1.X-Vingmed). All
strain images were obtained at a frame rate of 59–82 frame/s.
Three consecutive cardiac cycles were acquired at end expira-
tion breath holding and digitally stored on a hard disk for
off-line analysis. In order to measure the timing of cardiac
events, LV inﬂow (mitral) and outﬂow (aortic) velocities were
recorded using Pulsed wave Doppler.
Longitudinal strain and strain rate were assessed in the 6 LV
walls and the software algorithm automatically segmented the
LV into an 18 equidistant segment model in a ‘‘bull’s eye’’ plot
and each segment was individually analyzed. The average value
of peak longitudinal strain (Esys%), the average value of peak
systolic strain rate (SRs s1), peak early diastolic strain rate
(SRe s1), and peak late diastolic strain rate (SRa s1) were mea-
sured at each segment (basal, mid and apical) then the global LV
strain and the global LV systolic and diastolic SR were obtained
from averaging the peak values of 18 LV segments and used for
comparison between control and hypertensive groups.5. Measurement of brain natriuretic peptide (BNP)
All samples were collected within 2 h of obtaining the echocar-
diogram. Plasma was separated by centrifugation and stored at70 C. Analysis was done using BNP-32 (Human) Kit
(ELISA).11
5.1. Statistical analysis
Data were tabulated and statistical analysis was performed
using the SPSS version 17 on an IBM compatible computer.
Quantitative data were expressed as mean and standard
deviation and analyzed by applying unpaired student t- test
for comparison of two groups of normally distributed vari-
ables and ANOVA (F test) for more than two groups and
Tukey’s test as a post hoc test.
Qualitative data were expressed as number and percentage
and analyzed by applying chi-square test (·2).
Pearson’s correlation coefﬁcient (r) was used to estimate
correlation between continuous variables and Receiver Oper-
ating Characteristic (ROC) curves were constructed to explore
the optimal cutoff point of peak systolic strain, systolic strain
rate, early and late diastolic strain rates as determinants of LV
dysfunction that would discriminate between hypertensive
patients and controls.126. Results
6.1. Clinical, demographic and electrocardiographic
characteristics
In the present study, there were no signiﬁcant differences
between the three groups as regards age and sex by inclusion
criteria (Tables 1 and 2).
ECG voltage criteria of LVH were present in 40% of hyper-
tensive patients (30% of group II and 70% of group III) but
they were absent in group I (control) (Table 2).
The BNP level was signiﬁcantly higher in hypertensive
patients with LVH (group III) than in the control group
(group I) and hypertensive patients without LVH (group II)
(Fig. 1).
6.2. Conventional echocardiography and Doppler tissue imaging
Left ventricular posterior wall thickness (PWd), interventricu-
lar septal thickness (IVSd), LA dimensions, left ventricular
mass (LVM) and left ventricular mass index (LVMI) were
higher in hypertensive patients with LVH (group III) than
hypertensive patients without LVH (group II) and the control
group (group I), while E/A ratio was lower in hypertensive
patients (groups II and III) than in the control group (group
I) (Table 3).
Regarding the DTI, the septal and Lateral Em peak veloc-
ities demonstrated a stepwise decrease from group I (control)
to group II (HTN without LVH) to group III (HTN with
LVH), while an opposite stepwise increase was shown in E/
Em ratio that increased from group I (control) to group II
(HTN without LVH) to group III (HTN with LVH) as shown
in Table 3.
6.3. 2D-speckle tracking imaging
Comparing the three groups as regards longitudinal peak
systolic strain demonstrated a signiﬁcant stepwise decrease of
Figure 1 BNP level in the studied groups. BNP, brain natriuretic peptide; LVH, left ventricular hypertrophy.
Table 1 Comparison between the study groups regarding demographic and clinical data.
DATA Group I Group II Group III ANOVA Tukey’s test
(Control) (No LVH) (With LVH)
Mean ± SD Mean ± SD Mean ± SD F P-value P1 P2 P3
Age (year) 50.5 ± 6.0 51.6 ± 5.1 52.2 ± 6.0 6.138 0.130 0.29 0.36 0.12
BSA (m2) 1.90 ± 0.10 1.94 ± 0.09 1.92 ± 0.06 6.973 0.224 0.190 0.146 0.472
BSA, body surface area; P1 = between groups II and III, P2 = between groups I and II, P3 = between groups I and III. P
value > 0.05 = insigniﬁcant, P< 0.05 = signiﬁcant, P< 0.001 = highly signiﬁcant.
Table 2 Comparison between the study groups regarding the gender and presence of ECG voltage criteria of LVH.
Groups Chi-square
Group I Group II Group III Total X2 P-value
(control) (No LVH) (With LVH)
N= 20 N= 40 N= 40 N= 100
Sex
Female N (%) 12 (60%) 24 (60%) 19 (47%) 55 (55%) 1.515 0.469
Male N (%) 8 (40%) 16 (40%) 21 (53%) 45 (45%)
ECG-LVH
Negative N (%) 20 (100%) 28 (70%) 12 (30%) 60 (60%) 62.48 0.0001
Positive N (%) 0 (0%) 12 (30%) 28 (70%) 40 (40%)
LVH, left ventricular hypertrophy. P< 0.0001 = highly signiﬁcant.
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without LVH) to group III (HTN with LVH) (Table 4 and
Fig. 2).
Furthermore, the global peak systolic strain rate (SRs s1)
was signiﬁcantly decreased in group III (HTN with LVH)
when compared to group I (control) and group II (HTN
without LVH) (Table 5).
The global early diastolic strain rate (SRe s1) showed a
signiﬁcant stepwise reduction from group I (control) to group
II (HTN without LVH) to group III (HTN with LVH)
(Table 5).
On the other hand, the global late diastolic strain rate
SRa s1 was signiﬁcantly increased in both group II
(HTN without LVH) and group III (HTN with LVH)
when compared to group I (control) as shown in
Table 5.Plasma BNP level was elevated among hypertensive groups
(groups II and III) than among controls and was markedly
higher among group III than group II (P= 0.001) (Table 3).
Additionally, the study showed a signiﬁcant negative correla-
tion between the mean value of BNP and the global peak sys-
tolic strain (Esys%) (r= 0.283, P= 0.01) as well as the
global SRs s1 (r= 0.301, P= 0.007), global SRe s1
(r= 0.374, P= 0.001) and global SRa s1 (r= 0.221,
P= 0.049) in hypertensive groups as illustrated in Fig. 3.
Among the hypertensive patients, a signiﬁcant negative cor-
relation was evident between E/Em ratio and each parameter
of Esys% (r= 0.542, P= 0.001), SRs s1 (r= 0.377,
P= 0.002), SRe s1 (r= 0.470, P= 0.001) and SRa s1
(r= 0.589, P= 0.001) (Fig. 4). Similarly, there was also a
signiﬁcant negative correlation between the LVMI and each
parameter of Esys% (r= 0.307, P= 0.006), SRs s1
Table 3 Comparison between the study groups by conventional echocardiography and Doppler tissue imaging.
Group I Group II Group III ANOVA Tukey’s test
(Control) (No LVH) (With LVH)
Mean ± SD Mean ± SD Mean ± SD F P-value P1 P2 P3
FS% 36.30 ± 3.326 36.60 ± 3.185 37.73 ± 3.588 1.629 0.201 0.301 0.944 0.277
EF% 65.60 ± 4.547 66.23 ± 4.022 67.58 ± 4.437 1.719 0.185 0.342 0.856 0.219
PWd (cm) 0.88 ± 0.120 0.93 ± 0.159 1.16 ± 0.087 46.675 0.0001 0.0001 0.323 0.0001
LVESd (cm) 3.02 ± 0.324 2.95 ± 0.272 3.130 ± 0.465 2.387 0.097 0.081 0.770 0.526
LVEDd (cm) 4.80 ± 0.494 4.55 ± 0.666 5.03 ± 0.328 8.544 0.0001 0.0001 0.208 0.222
IVSd (cm) 0.90 ± 0.123 1.00 ± 0.339 1.25 ± 0.085 19.810 0.0001 0.0001 0.218 0.0001
AO (cm) 2.95 ± 0.284 2.96 ± 0.377 3.11 ± 0.331 2.257 0.110 0.154 0.988 0.216
LA (cm) 3.06 ± 0.254 3.72 ± 0.385 4.03 ± 0.359 13.047 0.0001 0.0001 0.035 0.0001
LVM (g) 145.60 ± 27.50 147.05 ± 27.48 253.35 ± 24.56 142.5 0.0001 0.0001 0.98 0.0001
LVMI (g/m2) 76.05 ± 12.54 75.53 ± 14.56 132.28 ± 9.69 179.4 0.0001 0.0001 0.76 0.0001
E (m/s) 0.90 ± 0.20 0.70 ± 0.15 0.78 ± 0.16 8.950 0.0001 0.047 0.001 0.0001
A (m/s) 0.67 ± 0.19 0.91 ± 0.14 0.80 ± 0.19 3.636 0.030 0.048 0.037 0.025
E/A ratio 1.37 ± 0.30 0. 77 ± 0.34 0.97 ± 0.33 15.30 0.0001 0.049 0.001 0.0001
Septal Sm (m/s) 0.091 ± 0.018 0.089 ± 0.012 0.087 ± 0.011 0.395 0.68 0.870 0.889 0.653
Septal Em (m/s) 0.129 ± 0.029 0.113 ± 0.016 0.085 ± 0.020 22.135 0.0001 0.048 0.0001 0.0001
Septal Am (m/s) 0.089 ± 0.018 0.086 ± 0.027 0.083 ± 0.020 0.631 0.53 0.752 0.658 0.785
Lateral Sm (m/s) 0.091 ± 0.013 0.089 ± 0.014 0.084 ± 0.011 5.088 0.66 0.957 0.887 0.553
Lateral Em (m/s) 0.134 ± 0.033 0.120 ± 0.021 0.107 ± 0.030 5.554 0.005 0.047 0.040 0.005
Lateral Am (m/s) 0.088 ± 0.018 0.085 ± 0.027 0.082 ± 0.020 0.631 0.53 0.652 0.758 0.620
Em (m/s) 0.131 ± 0.025 0.116 ± 0.019 0.960 ± 0.021 14.223 0.0001 0.047 0.027 0.0001
E/ Em 6.923 ± 2.034 8.190 ± 0.546 11.052 ± 3.296 3.846 0.001 0.037 0.043 0.001
BNP (pg/ml) 68.15 ± 15.62 147.70 ± 24.65 250.38 ± 53.11 280.8 0.0001 0.0001 0.0001 0.0001
A: late diastolic ﬁlling; AO: aorta; Am: mitral annulus late diastolic velocity; BNP; brain natriuretic peptide; E: early diastolic ﬁlling; EF%:
ejection fraction; Em: mitral annulus early diastolic velocity; FS%: fractional shortening; IVSd: interventricular septum thickness in diastole;
LA: left atrium; LVEDd: LV end diastolic dimension in diastole; LVESd: LV end systolic dimension; LVM: left ventricular mass; LVMI: left
ventricular mass index; PWd: LV posterior wall thickness in diastole; Sm: mitral annulus peak systolic velocity. P1 = between groups II and III,
P2 = between groups I and II, P3 = between groups I and III, P value > 0.05 = insigniﬁcant, P< 0.05 = signiﬁcant, P< 0.001 = highly
signiﬁcant.
Table 4 Comparison between the study groups regarding LV cumulative peak systolic longitudinal strain (Esys%).
Cumulative
Esys%
Group I Group II Group III ANOVA Tukey’s test
(Control) (No LVH) (With LVH)
Mean ± SD Mean ± SD Mean ± SD F P-value P1 P2 P3
Septal 23.10 ± 3.339 19.70 ± 3.098 17.67 ± 3.108 19.82 0.0001 0.014 0.0001 0.0001
Lateral 19.95 ± 1.849 18.38 ± 3.232 16.43 ± 3.029 10.52 0.0001 0.010 0.126 0.0001
Inferior 23.50 ± 2.666 20.78 ± 3.669 19.03 ± 3.971 10.22 0.0001 0.084 0.020 0.0001
Anterior 20.40 ± 2.349 19.60 ± 3.795 17.73 ± 3.266 5.32 0.006 0.036 0.658 0.012
Posterior 24.10 ± 2.337 19.05 ± 2.773 19.60 ± 3.463 20.64 0.0001 0.691 0.0001 0.0001
Antero-Septal 21.15 ± 2.368 19.90 ± 4.088 18.65 ± 3.800 3.21 0.045 0.289 0.435 0.040
Global LV Esys% 21.90 ± 1.334 19.58 ± 2.395 17.13 ± 2.613 17.67 0.0001 0.037 0.011 0.0001
Esys%: peak systolic longitudinal strain; LVH: left ventricular hypertrophy. P1 = between groups II and III, P2 = between groups I and II,
P3 = between groups I and III, P value > 0.05 = insigniﬁcant, P< 0.05 = signiﬁcant, P< 0.001 = highly signiﬁcant.
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P= 0.003), while its correlation with SRa s1 did not reach
statistical signiﬁcance (r= 0.146, P= 0.196) as shown in
Fig. 5.
ROC curves were constructed to explore the optimal cutoff
point of peak systolic strain and strain rate that discriminated
LV dysfunction between hypertensive patients and controls
(Table 6, Fig. 6).
7. Discussion
2D-STE appears more sensitive than both conventional echo-
cardiography and DTI in identifying the reduction of intrinsicmyocardial contractility, evident in hypertensive patients even
long before LV hypertrophy becomes detectable as it was
observed from the present study that an impairment of longi-
tudinal systolic function was observed as detected by a signif-
icant reduction of LV systolic strain and systolic SR values in
hypertensive patients even without LVH as compared to con-
trols. Moreover, a signiﬁcant reduction in strain values was
found in hypertensive patients with LVH in comparison to
hypertensive patients without LVH. This ﬁnding highlights
the advantages of 2D-STE over DTI in the detection of early
impairment of LV systolic function.
Our results are in concordance with the ﬁndings of Kouzu
et al.13 who found that longitudinal strain was signiﬁcantly
Figure 2 2D STE measurement of longitudinal strain in apical 4-chamber view in a hypertensive patient without LVH, it shows
reduction of peak longitudinal strain of basal segments of septal and lateral walls (Esys%= 14% and 15% respectively) but normal
peak longitudinal strain of the remaining myocardial segments and normal global LV strain (GS = 22%). GS = global strain.
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subjects. Additionally, Imbalzano et al.14 revealed that 2D-
STE showed an impairment of systolic longitudinal strain in
all hypertensive patients including those without LVH. Again,
a study done by Saghir et al.15 revealed that hypertensive indi-
viduals with LVH had signiﬁcantly decreased systolic longitu-
dinal strain and strain rate values compared with control
subjects.
The latent longitudinal LV systolic dysfunction despite the
normal ejection fraction in hypertensive patients may be
explained partially by: (i) The compensatory augmentation
of LV circumferential shortening and twist as proven by
Imbalzano et al.14, who demonstrated that; STE revealed an
impairment of systolic longitudinal and radial strain and
increased circumferential strain and LV twist or torsion.
(ii) Myocardial ﬁbrosis which is one of the factors respon-
sible for myocardial function deterioration in hypertension.
In addition, chronic increase of end systolic wall stress may
promote subendocardial synthesis of collagen, contributing
to reduction of longitudinal deformation in affected patients
with normal EF.16 (iii) the compensatory augmentation of
LV circumferential shortening and twist as proven by Imbalz-
ano et al.14 who demonstrated that STE revealed an impair-
ment of systolic longitudinal and radial strain and increased
circumferential strain and LV twist. As LV ejection fraction
is measured in the parasternal long axis view, it is not affected
by reduction of longitudinal strain. (iv) Limited sensitivity of
EF was demonstrated by Edvardsen et al.17 who stated that
the apparently normal systolic function in heart failure
patients with normal EF reﬂects limited sensitivity of EF,
and assessment of regional systolic function by STE providesimportant diagnostic information. (v) EF is a volumetric mea-
surement; the geometric assumptions limit its usefulness in the
abnormal ventricle and the M-mode assessment provides
information about contractility along a single line while LV
global strain does not rely on such geometric assumptions,
but rather measures regional myocardial function with preci-
sion. In addition, LV global strain may be more sensitive to
changes in long-axis shortening than LV ejection fraction.18
Left ventricular hypertrophy is a common response to
increased and prolonged afterload and is associated with a
variety of alterations including; ﬁbrosis, impaired coronary
artery vasodilator capacity, depressed LV wall mechanics,
and abnormal LV diastolic ﬁlling pattern. Subendocardium
is susceptible to the deleterious effects of both interstitial ﬁbro-
sis and hypoperfusion, the impaired subendocardial function
results in abnormal longitudinal function which demonstrates
that myocardial strain pattern depends on LV adaptive
responses to high blood pressure.18
Furthermore, the present study showed a signiﬁcantly
reduced value of early diastolic strain rate in hypertensive
groups compared to the control group. Similar ﬁndings were
described by Yan19 who showed that the early diastolic strain
rate values were lower in essential hypertensive patients than in
controls. Hence, it was concluded that speckle tracking imag-
ing may be helpful for early detection of subclinical changes
in LV diastolic function in patients with hypertension. This
can be explained by increased myocardial ﬁbrosis in hyperten-
sive heart disease which is directly linked to abnormalities in
diastolic function and myocardial stiffness.20
RegardingDTIparameters, the present study showed reduced
Em and elevated E/Em ratio in both hypertensive groups
Figure 3 Relationship of BNP level in hypertensive patients to global peak systolic strain (Esys%) (A), global peak systolic strain rate
(SRs s1) (B), global peak early diastolic strain rate (SRe s1) (C) and global late diastolic strain rate (SRa s1) (D). BNP, brain natriuretic
peptide; Esys%: peak systolic strain; SRa s1: peak late diastolic strain rate; SRe s1: peak early diastolic strain rate; SRs s1: peak systolic
strain rate.
Table 5 Comparison between the study groups regarding Cumulative Peak Systolic Strain Rate (SRs s1), peak early diastolic strain
rate (SRe s1) and peak late diastolic strain rate (SRa s1).
Group I Group II Group III ANOVA Tukey’s test
(Control) (No LVH) (With LVH)
Mean ± SD Mean ± SD Mean ± SD F P-value P1 P2 P3
Cumulative SRs s1
Septal 1.075 ± 0.392 1.027 ± 0.274 0.939 ± 0.256 2.163 0.120 0.103 0.819 0.527
Lateral 1.208 ± 0.239 1.090 ± 0.265 0.939 ± 0.176 10.16 0.0001 0.011 0.147 0.001
Inferior 1.173 ± 0.173 1.160 ± 0.244 0.965 ± 0.253 8.966 0.0001 0.0001 0.98 0.009
Anterior 1.109 ± 0.277 1.100 ± 0.274 1.056 ± 0.204 0.469 0.627 0.626 0.993 0.798
Posterior 1.244 ± 0.174 1.105 ± 0.331 1.037 ± 0.299 3.309 0.041 0.555 0.201 0.031
Antero-septal 1.122 ± 0.165 1.079 ± 0.283 1.032 ± 0.344 0.671 0.513 0.754 0.853 0.502
Global LV SRs s1 1.145 ± 0.132 1.106 ± 0.206 0.994 ± 0.185 5.718 0.004 0.023 0.717 0.01
Cumulative SRe s1
Septal 1.396 ± 0.296 1.310 ± 0.340 1.011 ± 0.286 13.83 0.0001 0.0001 0.57 0.0001
Lateral 1.432 ± 0.337 1.285 ± 0.351 1.101 ± 0.367 6.31 0.003 0.018 0.29 0.003
Inferior 1.481 ± 0.230 1.395 ± 0.409 1.037 ± 0.429 12.16 0.0001 0.0001 0.70 0.0001
Anterior 1.440 ± 0.211 1.283 ± 0.380 1.101 ± 0.207 9.763 0.0001 0.016 0.12 0.0001
Posterior 1.469 ± 0.305 1.221 ± 0.495 1.194 ± 0.316 3.53 0.033 0.950 0.04 0.034
Anteroseptal 1.460 ± 0.375 1.140 ± 0.499 1.116 ± 0.370 4.87 0.010 0.965 0.02 0.011
Global LV SRe s1 1.446 ± 0.219 1.274 ± 0.288 1.093 ± 0.257 12.65 0.0001 0.008 0.03 0.0001
Cumulative SRa s1
Septal 0.777 ± 0.337 1.003 ± 0.288 1.019 ± 0.217 5.957 0.004 0.964 0.009 0.005
Lateral 0.705 ± 0.304 0.876 ± 0.336 0.922 ± 0.228 3.803 0.026 0.760 0.046 0.021
Inferior 0.750 ± 0.153 0.988 ± 0.307 1.132 ± 0.305 13.224 0.0001 0.286 0.0001 0.0001
Anterior 0.689 ± 0.167 0.964 ± 0.349 0.980 ± 0.213 8.863 0.0001 0.964 0.0001 0.0001
Posterior 0.722 ± 0.374 0.971 ± 0.317 1.047 ± 0.344 6.199 0.003 0.581 0.024 0.002
Antero-septal 0.603 ± 0.290 0.986 ± 0.333 1.155 ± 0.340 18.859 0.0001 0.060 0.0001 0.0001
Global LV (SRa s1) 0.711 ± 0.162 0.949 ± 0.235 1.043 ± 0.213 16.138 0.0001 0.125 0.0001 0.0001
SRs s1: peak systolic strain rate; SRe s1: peak early diastolic strain rate; SRa s1: peak late diastolic strain rate.P1 = between groups II and III,
P2 = between groups I and II, P3 = between groups I and III, P value > 0.05 = insigniﬁcant, P< 0.05 = signiﬁcant, P< 0.001 = highly
signiﬁcant.
LV deformation abnormalities in hypertensive patients 305compared to the control group. This goes in harmony with Mak
et al.21 who stated that Em value is load independent and E/Em
ratio can be used to estimate LV ﬁlling pressure as E/Em ratio
P15 is highly speciﬁc for elevated LV end diastolic pressure. This
was further conﬁrmed by Elnoamany and Abdelhameed22 whodemonstrated the ability of DTI derived parameters for evalua-
tionofLVﬁllingpressure andearly detectionofdiastolic dysfunc-
tion in patients with normal systolic function in contrast to
conventionalmitral inﬂowvelocities alonewhich correlate poorly
with LV ﬁlling pressure in such patients.
Table 6 ROC curve between patients and controls regarding esys%, SRs s1, SRe s1 and SRa s1.
Cutoﬀ Sensitivity Speciﬁcity PPV NPV Accuracy
Esys % >21% 80.0 90.0 97.0 52.9 0.855
SRs s1 >0.99 s1 43.7 95.0 97.2 29.7 0.662
SRe s1 >1.44 s1 82.5 65.0 90.4 48.1 0.760
SRa s1 >0.73 s1 92.5 75.0 93.7 71.4 0.854
Esys%: peak systolic strain; NPV, negative predictive value; PPV, positive predictive value; SRa s1; peak late diastolic strain rate; SRe s1:
peak early diastolic strain rate; SRs s1; peak systolic strain rate.
Figure 4 Relationship of E/Em ratio in hypertensive patients to global peak systolic strain (Esys%) (A), global peak systolic strain rate
(SRs s1) (B), global peak early diastolic strain rate (SRe s1) (C) and global late diastolic strain rate (SRa s1) (D). Esys%: peak systolic
strain; SRa s1: peak late diastolic strain rate; SRe s1: peak early diastolic strain rate; SRs s1: peak systolic strain rate.
Figure 5 Relationship of LVMI in hypertensive patients to global peak systolic strain (Esys%) (A), global peak systolic strain rate
(SRs s1) (B), global peak early diastolic strain rate (SRe s1) (C) and global late diastolic strain rate (SRa s1) (D). Esys%: peak systolic
strain; LVMI, left ventricular mass index; SRa s1: peak late diastolic strain rate; SRe s1: peak early diastolic strain rate; SRs s1: peak
systolic strain rate.
306 W.A.I. Hamed et al.The current study found that BNP level was higher among
both hypertensive groups than among controls and it was cor-
related with LV strain and strain rate values in those patients.
Moreover, the mean value of BNP was higher among patients
with LVH than patients without LVH. These ﬁndings are con-
sistent with the ﬁndings of Elnoamany and Abdelhameed22
who demonstrated that BNP levels were higher in patients with
combined systolic and diastolic dysfunction than those withonly systolic dysfunction. Additionally, patients with LV dila-
tation had a higher level of BNP than patients with normal LV
dimension, and all had signiﬁcantly higher BNP levels than
control group. It seems that LV diastolic ﬁlling impairment
is mainly responsible for the increased plasma levels of BNP
in hypertensive patients.
This was further conﬁrmed by Mouly-Bertin et al.23 who
demonstrated that BNP levels were higher in hypertensive than
Figure 6 ROC curve between hypertensive patient groups and control group regarding Esys% (A), SRs s1 (B), SRe s1 (C) and SRa s1
(D). Esys%: peak systolic strain; SRa s1: peak late diastolic strain rate; SRe s1: peak early diastolic strain rate; SRs s1: peak systolic
strain rate.
LV deformation abnormalities in hypertensive patients 307normotensive patients and more raised in LVH and in diastolic
dysfunction that could be related to cardiac remodeling in
hypertension. Additionally, Morillas et al.24 found a good rela-
tionship between plasma BNP concentration and left ventricu-
lar mass as determined by cardiac magnetic resonance in
hypertensive patients and concluded that assessment of BNP
level could be valuable in initial screening for LVH in asymp-
tomatic patients with high blood pressure, in follow up of
hypertensive patients and in monitoring of regression of
LVH with treatment. The high negative predictive value of
BNP makes its assessment useful for excluding cardiac dys-
function in the setting of emergency evaluation of symptoms
that mimic those of cardiac origin.23
8. Limitations
First, our study included subjects with different onset, severity
and treatment modalities of hypertension, the small number of
the study participants may have inﬂuenced our results. Second,
our results were based on the 2D echocardiographic technique
which is inferior to 3D echocardiography or magnetic reso-
nance imaging based measurements of LV mass and LV mass
index. Finally, the optimal frame rate for speckle tracking
echocardiography seems to be 50–70 frames/s which may
result in under-sampling, especially in patients with
tachycardia.
9. Conclusions
A substantial impairment of LV systolic and diastolic func-
tions is detected in hypertensive patients with apparently pre-
served LV systolic function, especially if associated with
LVH, as evidenced by two-dimensional speckle tracking echo-
cardiography. Plasma BNP level is elevated in hypertensive
patients and shows a signiﬁcant negative correlation with
strain and strain rate values.Conﬂict of interest
The authors declare that there is no conﬂict of interest regard-
ing the publication of this article.
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